|
TRU EBV-M and TRU EBV-G
The First Rapid
Tests for the Detection of EBV Specific Antibodies.
Epstein Barr
Virus (EBV) Clinical Features
EBV is a
Herpesvirus and one of the most common human viruses. Typical
manifestation of
primary infection is Infectious Mononucleosis (IM), a self-limited
clinical syndrome that most frequently affects
adolescents and young adults.
EBV Diagnosis
Clinical
diagnosis of infectious mononucleosis is
suggested on the basis of the symptoms of fever, sore throat, swollen
lymph
glands, and the age of the patient. As the symptoms may be overlapping
with
those of infections like CMV, HIV, Rubella, Parvovirus and Toxoplasma gondii, serological tests are
needed to confirm a
diagnosis.
Heterophile
antibody detection is frequently used for confirmation of a diagnosis
of acute
primary EBV infection but may lead to false positive (5%) and false
negative
(10 to 20%) results in adults. Under the age of 14, the test is
decreasingly
sensitive and false-negative results may be obtained in 10% to 50% of
children.
Importance
of Specific EBV Serology
Effective laboratory diagnosis can be made on a
single
acute-phase serum sample by testing for antibodies specific to EBV
antigens. A
crucial concern in EBV diagnosis is to distinguish acute from past
infection
and susceptibility to EBV. Three antibodies VCA IgG, VCA IgM and EBNA-1
IgG
enable to distinguish if a person is susceptible to EBV, has a primary
infection, has had infection in the past. Viral Capsid Antigens are
present in
every cell infected with EBV. During primary EBV infection VCA-IgM
appears
first and VCA-IgG antibodies develop shortly after and persist
lifelong. IgG
antibodies to EBNA-1 (Nuclear Antigen) appear weeks or months after the
acute
phase of infection and their presence together with VCA-IgG is
indicative of
past infection.
TRU
EBV
TRU EBV-M and TRU EBV-G tests are the first
rapid
tests designed to detect specific IgM and IgG antibodies to Epstein
Barr Virus
in less than 20 minutes. The test system is a simple, sensitive and
rapid
approach that allows healthcare provider s
to diagnose and stage EBV
infections.
The two tests are based upon Meridian’s
proprietary newest test TRU
platform which offers rapid and accurate
results in a
self-contained system.
Based on recombinant technology and highly specific
EBV proteins, TRU
EBV-M detects IgM
antibodies to VCA while TRU EBV-G is designed for the separate
detection
of IgG antibodies
to VCA and EBNA.
Click here for more
information on EBV-M and here
for EBV-G
MORE NEWS: ImmunoCard
Stat! EHEC - Rapid detection of Shiga like
Toxins
back to top
|
